Theravance Biopharma Stock Piotroski F Score
| TBPH Stock | USD 9.12 0.02 0.22% |
Theravance | Piotroski F Score |
At this time, it appears that Theravance Biopharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | Higher Leverage |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | Increase |
Theravance Biopharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Theravance Biopharma is to make sure Theravance is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Theravance Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Theravance Biopharma's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.08 | 0.1503 |
|
| |||||
| Total Current Liabilities | 23.5 M | 24.8 M |
|
| |||||
| Non Current Liabilities Total | 137 M | 144.2 M |
|
| |||||
| Total Assets | 418.6 M | 382 M |
|
| |||||
| Total Current Assets | 126.9 M | 133.5 M |
|
|
Theravance Biopharma F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Theravance Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Theravance Biopharma in a much-optimized way.
Click cells to compare fundamentals
About Theravance Biopharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
About Theravance Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theravance Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theravance Biopharma's short interest history, or implied volatility extrapolated from Theravance Biopharma options trading.
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out Theravance Biopharma Altman Z Score, Theravance Biopharma Correlation, Theravance Biopharma Valuation, as well as analyze Theravance Biopharma Alpha and Beta and Theravance Biopharma Hype Analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.